Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GERN Geron	$1.35 -0.7%	$1.38	$1.09 ▼ $4.83	$867.70M	0.73	11.28 million shs	8.76 million shs
RIGL Rigel Pharmaceuticals	$34.52 +3.2%	$21.14	$11.22 ▼ $35.17	$600.18M	1.21	486,539 shs	1.14 million shs
SPPI Spectrum Pharmaceuticals	$1.03	$1.01	$0.32 ▼ $1.57	$211.41M	2.15	1.93 million shs	N/A
ZBIO Zenas BioPharma	$15.90 +6.7%	$12.34	$5.83 ▼ $26.25	$623.54M	N/A	138,024 shs	98,042 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GERN Geron	+6.25%	+12.40%	+3.03%	+13.33%	-71.06%
RIGL Rigel Pharmaceuticals	+5.55%	+47.60%	+77.22%	+82.94%	+227.72%
SPPI Spectrum Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ZBIO Zenas BioPharma	+1.85%	-11.36%	+33.27%	+63.92%	+1,489,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GERN Geron	3.2902 of 5 stars	3.3	1.0	1.3	3.1	1.7	0.6
RIGL Rigel Pharmaceuticals	2.3717 of 5 stars	2.2	0.0	0.0	3.2	1.7	3.1
SPPI Spectrum Pharmaceuticals	0.396 of 5 stars	0.0	0.0	4.7	0.0	0.0	0.6
ZBIO Zenas BioPharma	1.8105 of 5 stars	3.5	0.0	0.0	2.8	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GERN Geron	2.56	Moderate Buy	$4.19	210.19% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	10.66% Upside
SPPI Spectrum Pharmaceuticals	0.00	N/A	N/A	N/A
ZBIO Zenas BioPharma	3.00	Buy	$36.67	130.61% Upside

Current Analyst Ratings Breakdown

Latest SPPI, GERN, ZBIO, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
7/10/2025	GERN Geron	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$1.00
5/16/2025	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$35.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GERN Geron	$76.99M	11.19	N/A	N/A	$0.41 per share	3.29
RIGL Rigel Pharmaceuticals	$179.28M	3.45	$1.11 per share	31.01	$4.57 per share	7.55
SPPI Spectrum Pharmaceuticals	$10.11M	20.91	N/A	N/A	$0.15 per share	6.87
ZBIO Zenas BioPharma	$5M	133.02	N/A	N/A	$7.48 per share	2.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GERN Geron	-$174.57M	-$0.13	N/A	N/A	N/A	-53.52%	-31.37%	-16.01%	N/A
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	6.38	32.88	N/A	36.51%	438.89%	57.03%	N/A
SPPI Spectrum Pharmaceuticals	-$75.40M	-$0.36	N/A	14.71	N/A	N/A	-218.44%	-66.16%	N/A
ZBIO Zenas BioPharma	-$156.99M	-$3.55	N/A	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)

Latest SPPI, GERN, ZBIO, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	N/A	N/A	N/A	$1.25 million	N/A
8/12/2025	Q2 2025	ZBIO Zenas BioPharma	-$1.02	-$1.25	-$0.23	-$1.25	N/A	N/A
8/6/2025	Q2 2025	GERN Geron	-$0.03	-$0.02	+$0.01	-$0.02	$47.30 million	$49.04 million
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million
5/15/2025	Q1 2025	ZBIO Zenas BioPharma	-$1.15	-$0.80	+$0.35	-$0.80	$5.00 million	$10.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GERN Geron	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GERN Geron	0.46	7.87	6.79
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90
SPPI Spectrum Pharmaceuticals	N/A	2.71	2.38
ZBIO Zenas BioPharma	N/A	6.47	6.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GERN Geron	73.71%
RIGL Rigel Pharmaceuticals	66.23%
SPPI Spectrum Pharmaceuticals	21.67%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
GERN Geron	7.42%
RIGL Rigel Pharmaceuticals	9.04%
SPPI Spectrum Pharmaceuticals	2.70%
ZBIO Zenas BioPharma	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GERN Geron	229	638.02 million	590.68 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.32 million	Optionable
SPPI Spectrum Pharmaceuticals	86	205.25 million	199.70 million	Optionable
ZBIO Zenas BioPharma	N/A	41.83 million	34.93 million	N/A

SPPI, GERN, ZBIO, and RIGL Headlines

Recent News About These Companies

Zenas BioPharma reports Q2 EPS ($1.25) vs ($24.23) last year

August 12 at 4:31 PM | msn.com

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 12 at 7:05 AM | globenewswire.com

44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.

August 9 at 3:59 AM | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?

August 6, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?

August 5, 2025 | marketbeat.com

3 Highly Shorted Stocks That Could Be the Next Wall Street Sensations

August 2, 2025 | msn.com

Zenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's Why

July 29, 2025 | marketbeat.com

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

July 28, 2025 | seekingalpha.com

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.5% - Time to Sell?

July 26, 2025 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 11.2% - Here's Why

July 14, 2025 | marketbeat.com

Innovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharma

July 3, 2025 | tipranks.com

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2025 | globenewswire.com

ZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...

June 17, 2025 | stockhouse.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 17, 2025 | prnewswire.com

Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)

June 16, 2025 | accessnewswire.comA

ZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 16, 2025 | globenewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

June 16, 2025 | globenewswire.com

June 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky

June 16, 2025 | accessnewswire.comA

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 16, 2025 | accessnewswire.comA

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

June 16, 2025 | businesswire.com

Securities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025

June 16, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPPI, GERN, ZBIO, and RIGL Company Descriptions

Geron NASDAQ:GERN

$1.35 -0.01 (-0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 +0.00 (+0.37%)

As of 07:58 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$34.52 +1.06 (+3.17%)

Closing price 04:00 PM Eastern

Extended Trading

$34.64 +0.12 (+0.35%)

As of 07:51 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Zenas BioPharma NASDAQ:ZBIO

$15.90 +1.00 (+6.71%)

As of 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time